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Abstract
Background: The discrimination of bacterial meningitis (BM) versus viral meningitis (VM) shapes up as a problem, when
laboratory data are not equivocal, in particular, when Gram stain is negative.
Methodology/Principal Findings: With the aim to determine reliable marker for bacterial or viral meningitis, we subjected
cerebrospinal fluid (CSF) to a quantitative proteomic screening. By using a recently established 2D-DIGE protocol which was
adapted to the individual CSF flow, we compared a small set of patients with proven BM and VM. Thereby, we identified six
potential biomarkers out of which Prostaglandin-H2 D-isomerase was already described in BM, showing proof of concept. In
the subsequent validation phase on a more comprehensive collective of 80 patients, we could validate that in BM high
levels of glial fibrillary acidic protein (GFAP) and low levels of soluble amyloid precursor protein alpha/beta (sAPPa/b) are
present as possible binding partner of Fibulin-1.
Conclusions/Significance: We conclude that our CSF flow-adapted 2D-DIGE protocol is valid especially in comparing
samples with high differences in total protein and suppose that GFAP and sAPPa/b have a high potential as additional
diagnostic markers for differentiation of BM from VM. In the clinical setting, this might lead to an improved early diagnosis
and to an individual therapy.
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Introduction
Patients with meningitis do not always display typical clinical
signs or characteristic laboratory parameters at the time of
admission, even when the bacterial origin could be proven later on
[1,2]. Meningism is often missing especially in elderly patients [1]
and young children [3]. Typical laboratory parameters in patients
with bacterial meningitis are elevated CSF-leukocytes $1000/ml
[4], CSF-protein $1 g/l [5], and CSF-lactate .3.0 mmol/l [6].
In blood samples, increase of leukocytes and of C-reactive protein
(CRP, usually $100 mg/ml) can be found [7].
Nevertheless, patients at an early stage of the disease or after
antimicrobial pre-treatment often show normal or inconclusive
routine parameters [8,9,10,11], so that further laboratory
parameters to differentiate the meningitis would be beneficial.
Actual, a mere pragmatic therapeutical proceeding is applied:
every patient under the strong suspicion of meningitis is treated
with a triple therapy of antiinfectious agents to cover as much
pathogens as possible. This is a practical approach, but there are
several reasons to improve the early treatment regime: firstly, there
are adverse reactions that are underestimated especially in elderly
patients and those with reduced renal function, leading to clinical
complications other than meningitis-associated with the conse-
quence of an extended hospitalisation. In the second place,
pathogen-resistance against frequent and blindfold applied anti-
infectives is a serious problem particularly with regard to the next
ten or twenty years with the high risk of forfeiting therapeutic
options. For these reasons, economic and specific application of
pharmaceuticals is the basis for best efficient therapy–however, a
precedent condition for this approach is the precise diagnosis.
The aim of our study was the identification of additional
supportive proteins for the differentiation of meningitis, particu-
larly with regard to those cases that are not clearly to be diagnosed
at the first presentation. To minimize the inclusion of misdiag-
nosed patients, we deliberately concentrated here on cases with
proven meningitis to find proteins that are typically involved in the
pathophysiology of the disease. Recently we could establish a
protocol especially for CSF proteomics, taking care to the fact that
brain derived proteins in CSF are independent of total CSF-
protein [12].
As methodical approach, we used fluorescent dye labelling,
compatible with protein isoelectric focussing (2D-DIGE). The 2D-
DIGE nowadays has the potential power to separate several
thousand proteins on a single gel and has become a method of
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e10079choice for quantitative proteomics [13,14]. On that basis, we used
this approach for the diagnosis of BM, with a special emphasis on
differentiation from VM. We identified six promising marker-
proteins out of more than 2500 spots. With the routinely
established protein-biochemical methods ELISA and Westernblot-
ting, these markers were then validated in a larger patient cohort.
Results
Patient data
For summary of all patient data see Table 1.
In the meningitis group, Streptococcus pneumoniae was identified in
15 patients, Neisseria meningitidis in three times. Five patients had
Listeria monocytogenes and in five patients Staphylococci aurei were
isolated.
Identification of potential biomarkers for BM
In the 2D-DIGE approach we obtained more than 2500 spots.
Searching for spots which had a significant higher spot volume (at
least 2.0 times different) and a p-value below 0.05, we received 10
candidates matching this criterion. After staining with colloidal
coomassie and mass spectrometric protein identification based on
peptide mass and sequence information obtained by MALDI-
ToF-MS, six out of 10 candidate proteins were identified
(Figure 1). Figure 2 and Table 2 as well as Figure S3 and Table
S1 illustrate data of spot identification.
Preclinical-validation of proteins relevant for differential
diagnosis
Prostaglandin-H2 D-isomerase and Haptoglobin. As the
Prostaglandin-H2 D-isomerase (or prostaglandin-D-synthase/b-
trace) was already described in the differential diagnosis of BM
[15,16], we refrained from validating this protein. Concerning
Haptoglobin, others found a diagnostic relevance within the 1
st
and 14
th day of disease, so that we did not follow-up this protein
[17].
Fibulin-1, Fibrinogen beta chain and Apolipoprotein E.
For Fibulin-1, Fibrinogen beta chain and Apolipoprotein E,
immunoblotting was done as validation step (data not shown). For
Fibrinogen beta chain (Figure S1), we detected elevated levels in BM
in comparison to CON (p=0.005) but not a difference between BM
versus VM (p=0.131).
For Fibulin-1 as well as Apolipoprotein E, no difference could
be seen in the 1D immunoblots. Assuming different isoforms of
these proteins, we performed 2D immunoblots for Fibulin-1 as
well as Apolipoprotein E and found in the case of Fibulin-1 a wide
distribution of isoforms (Figure S2), which were suggestive for
different isoform-allocation, but difficult to be differentiated by
2D-immunoblot.
Fibulin-1, sAPPa and sAPPb. Because of the above
mentioned different isoforms of Fibulin-1 in the 2D immunoblot,
we investigated binding proteins of fibulin-1 like APP-processing
products [18,19]. In a pilot experiment, we investigated sAPPa/b
in a small cohort of patients (10 BM, 10 VM and 10 CON) using
multiplex ELISA [20]. Here, significantly decreased sAPPa/b
values for BM in comparison to VM and CON were detected
(p=0.001) (Table 3 and Figure 3A/B).
GFAP ELISA of CSF and serum samples. For GFAP, a
commercially available ELISA was performed, identifying a
significant increase in patients with BM (p,0.001) in
comparison to VM and CON. As GFAP levels in BM were out-
of range of the standard curve, dilutions of up to 1:50 had to be
applied.
As the CSF-GFAP values in BM patients differed in both
centers (Ulm 7 patients and Go ¨ttingen 21 patients), separate
analyses of the data were performed. In VM (27 patients) as well as
CON (25 patients), no differences between the centers were found.
In serum, we could not detect different values of GFAP in a pilot
experiment (10 patients per group, p=0.068, Figure 3C/D and
Table 4).
Correlations
To test correlations between GFAP and standard parameters of
CSF, we calculated Spearman correlations that are listed in
Table 5.
Discussion
In the differential diagnosis of early stages of BM, routine
laboratory results can be misleading [21]. CSF-leukocyte counts
can be lower than 100/ml [22] heralding a severe clinical course,
the CSF-leukocyte differentiation is also not an accurate tool:
when the leukocyte count is below 1000/ml, more than 30% of
patients show a CSF-lymphocytosis [23]. CSF-lactate concentra-
tion seems to be more reliable [24], here a cut-off value of
3.0 mmol/l was proposed by Berg and co-workers [6]. Neverthe-
less, two of their patients in rather early stages showed lactate
concentrations below this cut-off. Although the additional
measurement of serum CRP appears to be a good marker for
the differentiation of BM versus VM [25], there still is a diagnostic
uncertainty [7,26].
Regarding biomarker approaches, two main hypothetical
factors for analysis can be opted: firstly, the investigation of
proteins specifically related to microbial pathogenicity like
secreted/surface or immunogenetic proteins, as often performed
by protein-biochemical methods. Here, multiplex PCR with
primer sequences to detect both, bacterial [27,28] as well as viral
DNA [29] represents a suitable method in cases with either
clinically suspected bacterial or viral origin of the CNS infection.
Table 1. Illustration of cardinal patient data.
group n age m/f leukocyte count/ml Lactate (mmol/l) QAlb (610
3) total protein (mg/l)
BM 1 7 49612 4/3 807861082 17.169.0 167363946 360661668
BM 2 21 55614 13/8 425166018 10.467.1 70362262 381664658
VM 25 53621 15/10 72692 1.960.4 10657 5 3 6335
CON 27 37620 19/8 ,5 ,2.0 ,8 ,450
Table 1 indicates age, CSF-leukocyte count, CSF-lactate, QAlb and total protein that are declarated as mean6SD.
Abbreviations: QAlb = CSF/serum albumin quotient; CSF = cerebrospinal fluid; BM1 = bacterial meningitis of center 1; BM 2 = bacterial meningitis center 2; VM = viral
meningitis; CON = controls; m/f = male/female.
doi:10.1371/journal.pone.0010079.t001
Proteomics in Meningitis
PLoS ONE | www.plosone.org 2 April 2010 | Volume 5 | Issue 4 | e10079The second basis for biomarker research is the identification of
proteins representing the host-specific response to a damaging
agent–usually performed as proteomic approach and better
applicable in those cases where the underlying pathogenic agent
is not to be anticipated.
We therefore decided on a proteomic approach to search for
additional biomarkers. As methodical technique, we used our
CSF-optimised, volume-based 2D-DIGE [12], a recently
published approach that takes the physiological CSF-flow of
proteins into consideration. Roughly 70% of lumbar CSF used
for diagnostic approaches consists of blood-derived proteins
especially albumin and immunoglobulins. However, the com-
position of ventricular CSF is quite different. The amount of
blood derived proteins is lower so that proteins feature a
concentration gradient from the ventricular space towards the
lumbar part, increasing in the case of blood-proteins and
decreasing in the case of intracerebral-proteins [30,31,32]. Even
after depletion of the major high abundand proteins, lots of
proteins are still blood-derived, so that an artificial normalisa-
tion to total protein amount in CSF can lead to wrong
assumptions traced back to the mainly detected blood-derived
proteins [12]. This still hold true after albumin and immuno-
globulin depletion. Our just established approach should be
preferred for CSF proteomics, especially for inflammatory
diseases and neurodegenerative disorders where a reduced
CSF-flow can be observed with the consequence of high total-
protein levels of which BM is an extreme-model.
Using this 2D-DIGE, we detected six relevant proteins for the
differential diagnosis of BM versus VM. For this proteome step,
only few patient samples were included being a critical point of
the study but our volume based proteome-method represents a
p r o o f - o fc o n c e p tc o n f i r m e db yt h ef a c tt h a tw ed i dn o ti d e n t i f y
blood-derived proteins. By standarization towards total protein
amount, we would have missed GFAP as diagnostic marker, as
in BM higher total protein amounts can be observed. However
for the initial proteomic approach, very few patients were used
so that we possibly have missed some markers which were
different in BM compared to VM, but did not match our strict
criteria we used for later validation. Also in this respect, BM is a
model disease as a clear differentiation between BM and VM is
necessary and an overlap even is some patients would be a
reason not to follow- up such a candidate marker. Having in
mind that we used for our initial proteomic screen only some
clear well defined patients, the following validation step is even
more important. This was done in our study, especially as we
even used samples from two independent centers to avoid the
measurement of a center-effect. A more comprehensive patient
collective in the subsequent preclinical validation phase was
Figure 1. 2D-DIGE - Illustration of the spots of interest. The 2D-DIGE gel of CyDye-labelled CSF proteins demonstrates four BM patients and
four VM patients. The figure illustrates the identified proteins, numbered from I to VI. BM samples are demonstrated by the green-colored spots and
are labelled with Cy 3; VM samples are demonstrated by the red-colored spots and are labelled with Cy 5. The red spot below GFAP is PEDF that in
the sum of all gels is not regulated.
doi:10.1371/journal.pone.0010079.g001
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PLoS ONE | www.plosone.org 3 April 2010 | Volume 5 | Issue 4 | e10079Figure 2. 2D-DIGE - Detailed information of the proteins of interest. 2D-DIGE analyses with pixel volume distribution of the proteins I–VI,
shown in figure 1 from numbers 1–4 BM, numbers 1–4 VM and average volume increased ratio. Using the DeCyder BVA Software, a Student’s t-test
applied to the four paired samples yielded a p-value within the 95
th percentile confidence level.
doi:10.1371/journal.pone.0010079.g002
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ical methods. Here, we decided on the basis of the spot volume
data to pursue the examination of GFAP with regard to its
differentially diagnostic potential. Using ELISA, highest levels
c o u l db es e e ni nB Mt h a tc o u l d-i nap i l o te x p e r i m e n t-n o tb e
reproduced in serum.
Interestingly, we found different concentrations of GFAP in
both centers with higher levels in center one. For VM and CON,
these variations of protein concentration did not appear. To
exclude at least - as a possible reason for this difference - distinct
pre-treatment protocols, we performed thaw/freezing cycles of
CSF and found a tendency of GFAP-decreased concentrations,
indicating the importance of preanalysis for research and the need
to take this into account by interpretation of the study-results.
However, in center two the time between storage and freezing was
up-to one week that could emerge as a possible cause for lower
GFAP in the samples.
To estimate the clinical importance of GFAP, we compared its
values with the routine standard parameters and found no
correlations in the BM group and a barely correlation between
GFAP and leukocyte count for VM. Because of this diagnostic
independence, we suppose that the measurement of GFAP has a
potential as additional marker for the diagnosis of BM.
The failure to validate proteins like Fibulin-1 as well as
Apolipoprotein E in the 1D immunoblot might be caused by the
proteomic approach itself, the available detection antibodies and the
fact that we might not detect the special isoform which was seen in
the proteomic approach. On the basis of the 2D immunoblot data
showing a different isoform pattern of Fibulin-1, we assumed a
pathophysiological relevance of this protein in meningitis. Never-
theless, the results imply that not only this protein but also other
proteins known to co-function with or be regulated by Fibulin-1 are
changed with respect to CSF expression levels. Since Fibulin-1 is
known to be involved in APP regulation, we had a closer look to this
protein [19]. For sAPPa/b, we found significantly decreased levels
in BM, possibly explaining the low levels of Ab1-42 in CSF of BM
which were described by others [33] as a phenomenon of less or
downregulated APP that is available for further processing. In BM,
we could also see a significant negative correlation of GFAP and
sAPPa, so that a combined analytical investigation of these proteins
might be of differential diagnostic relevance. Regarding APP in
patients with AD, Blennow et al. found no different levels of sAPPa/
b in comparison to controls suggesting no change in APP expression
in sporadic AD [34]. Mattsson et al. investigated the activity of the
b-site APP cleaving enzyme (BACE1) in CSF of patients with
multiple sclerosis. BACE1 cleaves APP which results in the release of
N-terminal b-cleaved sAPPb. They found reduced levels of sAPPa/
b compared to controls, but the reductions in sAPP products seem
not to be specific to MS because of similar results seen in Lupus
erythematodes as an example of another autoimmune disease [35].
Regarding the biological relevance as well as the pathophysi-
ological aspects of GFAP in meningitis, a probable astrogliosis
followed by bacterially triggered inflammation of the CNS could
be the morphological correlate of the observed GFAP release into
the CSF. It is not yet clear if this astroglia-proliferation is due to
bacterial toxins or to overwhelming activation of early immune
responses [36].
Best investigations of astrogliosis were performed in chronic
multiple sclerosis and in mouse models of experimental autoim-
mune encephalomyelitis (EAE) [23]. Here, an overexpression of
GFAP was detected that is discussed to be essential for normal
white matter architecture and its absence is said to cause late-onset
CNS dysmyelination [37]. Moreover, recent data based on the
EAE-model indicate increased GFAP-levels being a promising
marker of the chronic disease stage in generally and of the
secondary progressive disease phase in particular in patients with
multiple sclerosis [38]. Similar investigations concerning disease
conversion from clinically mild stages to more severe forms
showed antigen detection of measles, rubella and varicella zoster
(the so called MRZ-reaction) having prognostic relevance to
predict conversion to MS in patients with a clinically isolated
syndrom [39].
Apart from these data, a discriminative aspect of GFAP in BM
and VM has not yet been evaluated. Moreover, we were able to
demonstrate a proof-of-concept for this protein concerning
proteomic approaches with subsequent validation by protein-
biochemical approaches.
As GFAP is possibly less dependent on antibiotic treatment in
the early phase of CNS infection than CSF-lactate and CSF-
leukocyte count, its measurement might be useful in situations
where patients have been pre-treated with antimicrobial agents.
Table 2. 2D-DIGE analyses and identification of selected CSF proteins.
Spot No. p value t-test Ratio BM/VM Protein name Swiss-Prot accession MW [kDa] pI
I 0.025 2.79 Fibulin-1 P23142 81.3 5.1
II 0.0063 3.50 Glial fibrillary acidic protein P14136 49.9 5.4
III 0.017 22.21 Fibrinogen beta chain P02675 56.6 8.5
IV 0.031 22.60 Haptoglobin P00738 45.9 6.1
V 0.006 5.48 Apolipoprotein E P02649 36.2 5.7
VI 0.006 7.13 Prostaglandin-H2 D-isomerase P41222 21.2 7.7
Table 2 illustrates cardinal data, including Swiss Prot accession number, MW and pI.
Abbreviations: BM/VM = bacterial/viral meningitis; MW = molecular weight; pI = isoelectric point.
doi:10.1371/journal.pone.0010079.t002
Table 3. Multiplex data of sAPPa/b.
group n
sAPPa in mg/ml as
mean±SD
sAPPb in mg/ml as
mean±SD
BM 10 22.81619.45; [613.92] 10.5169.43; [66.75]
VM 10 73.03629.71; [621.25] 45.31614.83; [610.61]
CON 10 73.01623.99; [617.16] 43.94610.24; [67.33]
Data of multiplex enzyme linked immunosorbent assay for sAPPa as well as
sAPPb in BM, VM and CON, comprising 10 patients per group. The 95% CI for
each group is indicated in brackets.
Abbreviations: sAPPa/b = soluble amyloid beta precursor protein.
doi:10.1371/journal.pone.0010079.t003
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may be of further relevance in the differential diagnosis of
meningitis, maybe reflecting pre-synaptical pathological [40] or
protective processes [18] as seen in neurodegenerative diseases like
AD [41,42]. Further studies with the aim to validate the role of
APP–best with robust tests for sAPPa/b–in the clinical workflow
will investigate if this protein is a complementary marker in those
cases where GFAP levels are not pathbraking. Additional
investigations with an inhomogeneous group of patients in a
routine setting should be performed to evaluate the diagnostic
relevance and the reproducibility of these biomarkers.
Materials and Methods
Ethics Statement
This study was conducted according to the principles
expressed in the Declaration of Helsinki. Taking of the CSF
and blood samples from humans were conducted with the
approval of the local ethics committee (Ethik-Kommission der
Medizinischen Fakulta ¨t der Universita ¨ten Ulm und Go ¨ttingen,
approval numbers: 8801 and 100305). All patients provided
written informed consent for the collection of samples and
subsequent analysis.
Figure 3. GFAP and sAPPa/b - Data of the ELISA and Multiplex. Boxplots of sAPPa (3A) as well as sAPPb levels (3B) in CSF of patients with BM,
VM and CON are indicated. Part 3C and 3D demonstrates GFAP-levels in CSF (3C) and serum (3D). In CSF, the comparison between center one and
center two is indicated for BM. Plot shows 10th, 25th, 50th, 75th, and 90th percentiles and outliers.
doi:10.1371/journal.pone.0010079.g003
Proteomics in Meningitis
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To discover potential biomarkers, we investigated CSF of 8
patients (4 BM, 4 VM, sample bank: University hospital Ulm) in
the proteomic approach. For the validation phase, a larger
collective comprising up to 80 patients, prospectively collected
between 2007/2008 (University hospitals in Ulm [center one] and
Go ¨ttingen [center two]) was used (28 BM, 25 VM and 27 CON).
After routine analysis of native CSF, supernatants were
aliquoted and stored at 280uC in Ulm within two hours. In
Go ¨ttingen, CSF was kept at 4uC up to one week before final
storage at 280uC. Samples were collected and aliquoted in
polypropylene cups. Patients with intracerebral or subarachnoidal
haemorrhage, chronic inflammatory diseases like multiple sclero-
sis, autoimmune diseases, seizures without signs of CNS-infection,
symptoms traced back to psychiatric indispositions or meningitis
signs of undefined etiology were excluded. For BM, only patients
with positive microbiological verification (either by blood culture,
CSF culture, Gram stain, PCR or agglutination tests) were
included [43,44]. The diagnosis of VM was performed by the
leukocyte count, the usual cell-staining, the lactate concentration
as well as the specific identification of HSV1 that was the causing
agent in 3 cases. A positive PCR on the first days of infection or an
antibody index above at least 1.6 after one to two weeks is a
precondition to assume an infection with this viral agent.
CyDye Labelling
Proteomic analysis via 2D-DIGE was done with a volume-based
normalization as described previously [12]. CSF samples were
albumin- and immunoglobulin-depleted (depletion kit, GE
Healthcare) according to the manufacturer’s instructions with
the exception, that 750 ml of the slurry was used per 1 ml original
volume of CSF. For CSF proteome comparison, four CSF samples
of each group were compared by the mixed internal standard
methodology described by Alban [45]. Each sample (400 ml CSF,
approximately 80–120 mg) was labelled with 200 pmol of Cy3 and
Cy5. The single samples were labelled either Cy3 or Cy5 for a
dye-switched comparison to avoid potential dye-to-protein pref-
erences. The mixed internal standard contains aliquots of each
individual sample (corresponding to 100 ml CSF) and was labelled
with Cy2 in the same dye-to-CSF ratio. The samples were
combined and diluted 1.33x by a stock solution for subsequent
IEF.
2D Gel Electrophoresis and Imaging
IEF was also done as described previously [12]. Second
dimension SDS-PAGE was performed with homogeneous 12.5%
gels (2546200 mm) according to Tastet et al. [14] at 3.5 W/gel
overnight at 20uC. The fluorescence signals of the Cy-labelled
protein samples were imaged using a scanner recording emission
wavelengths of 520 nm (Cy2), 580 nm (Cy3) and 670 nm (Cy5)
(DIGE-Imager, GE Healthcare). Proteins were post-stained with
colloidal coomassie. Spots of interest were excised manually and
subjected to mass spectrometric protein identification.
In-gel digest and mass spectrometry
Manually excised gel plugs were subjected to an automated
platform for the identification of gel-separated proteins [46]. Using
an Ultraflex MALDI-ToF mass spectrometer (Bruker Daltonics), a
peptide mass fingerprint (PMF) and six fragment ion spectra for
each sample were recorded automatically under the control of the
FlexControl 3.0 operation software (Bruker Daltonics). PMF
spectra were calibrated externally on the basis of nine-point
near-neighbor calibrant spectra (Peptide Calibration Standard II,
Bruker Daltonics). Annotation of monoisotopic peptide signals in
the m/z range 800–4000 by the SNAP algorithm (S/N
threshold=4, quality factor threshold=50, number of peaks
limited to 100) and generation of the corresponding peak lists was
performed with the FlexAnalysis 3.0 post-processing software
(Bruker Daltonics). Background signals corresponding to typical
trypsin autolysis peptides and to a CHCA cluster at m/z 833 were
removed from the peak list. Fragment ion spectra were post-
processed as above with slightly different settings for the SNAP-
based peak detection (S/N threshold=3, quality factor thresh-
old=30, number of peaks limited to 200).
Database search
PMF and MS/MS data sets were batch-processed using the
BioTools 3.1 software (Bruker Daltonics) as interface to the Mascot
2.2 software (Matrix Science) licensed in-house. Database searches
were performed in the Swiss-Prot primary sequence database
Sprot 56.9 (release of 03-Mar-2009, 412525 entries), restricted to
the taxonomy homo sapiens (20402 entries). Carboxamidomethyla-
tion of Cys was specified as fixed and oxidation of Met as variable
modification. One trypsin missed cleavage was allowed. Mass
tolerances were set to 100 ppm for PMF searches and to 100 ppm
(precursor ions) and 0.7 Da (fragment ions) for MS/MS ion
searches. The minimal requirement for accepting a protein as
Table 4. ELISA of GFAP in BM and VM meningitis.
group
GFAP in CSF in ng/ml;
mean±SD
GFAP in serum in ng/ml;
mean±SD
BM 1 176.966195.30; [6180.63] 0.7561.23; [60.882]
BM 2 22.53632.37; [615.15] -
VM 2.9462.24; [60.944] 0.1060.15; [60.109]
CON 1.1560.77; [60.305] 0.0660.01; [60.008]
Because of distinct GFAP values in both centers (Ulm and Go ¨ttingen), we
performed separate analyses for the BM group. In CSF, 7 BM patients of center
1 (BM 1), 21 BM patients of center 2 (BM 2), 25 VM patients as well as 27 CON
patients were examined. In serum, ELISA was performed with 10 patients per
group. The 95% CI for each group is indicated in brackets.
doi:10.1371/journal.pone.0010079.t004
Table 5. Correlation of GFAP to routine CSF data.
tested parameter group r p
GFAP vs CSF-lactate BM 0.296 0.179
VM -0.064 0.765
GFAP vs QAlb BM 0.075 0.736
VM -0.022 0.917
GFAP vs CSF-total protein BM 0.266 0.228
VM 0.172 0.417
GFAP vs CSF-leukocyte count BM 0.136 0.541
VM -0.418 0.042
GFAP vs sAPPa BM -0.750 0.038
VM 0.750 0.038
GFAP vs sAPPb BM -0.679 0.074
VM 0.536 0.181
Illustration of Spearman correlation coefficient (r) with the respective p-values
(p). To test possible correlations between GFAP and standard parameters, we
performed Spearman correlations and found a negative/positive correlation
between GFAP and sAPPa in BM/VM.
doi:10.1371/journal.pone.0010079.t005
Proteomics in Meningitis
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threshold in coincidence with at least 20% sequence coverage
assigned in the PMF.
Westernblotting
Westernblotting was done according to standard protocols [12].
SDS-PAGE with 12% polyacrylamide gels was performed
according to Laemmli [47]. After first dimension, equilibration
and electrophoresis, proteins were transferred onto PVDF
membrane (Schleicher & Schuell, Germany) in semi dry blot
equipment [48]. The first antibodies were diluted 1:20000 (mAb
Apolipoprotein E, Epitomics #1930-1) and 1:1000 (mAb
Fibrinogen beta chain, American Diagnostics #ADI350) as well
as 1:500 (mAb Fibulin-1, Santa Cruz #sc-55470) in PBS, 0.0075%
Tween-20, containing 5% dry milk powder (Roth, Germany).
As secondary antibodies, peroxidase-conjugated goat anti-rabbit
Ig (Dianova, Germany, 1:2000, #111-035-003) or goat-anti
mouse (Dako, Germany, 1:2000, #P0447) were applied and
proteins were visualized by chemiluminescence according to the
manufacturer’s instructions (ECL plus, GE Healthcare).
Human GFAP ELISA
Human GFAP was detected via ELISA (BioVendor, Germany).
The assay was performed according to manufacturer’s instruc-
tions. The analytical limit of detection was 0.033 ng/ml [49].
Multiplex enzyme-linked immunosorbent assay
Multiplex ELISA for sAPPa/b was performed according to
manufacturers instructions (Meso Scale Discovery, USA). Con-
centrations were calculated from standard curves fitted by four
parameter equation using the supplied analysis software (meso-
scale). The analytical limit of detection was 120 pg/ml for sAPPa
and 52 pg/ml for sAPPb. For detailed instructions of this
multiplex ELISA see reference [50].
Statistical analysis
Band volumes (adjusted for membrane background) of the
immunoblots were determined using the Quantity One software
(BioRad, Germany). The comparison of protein concentrations
between the different subgroups was based on calculations using
Kruskal-Wallis test. Correlations were performed by Spearman
correlation. Calculations and comparisons were performed by the
software SigmaStat 3.5 (Systat Software Inc, USA).
Supporting Information
Figure S1 Westernblot-analysis of Fibrinogen beta chain. Band
volumes of fibrinogen beta chain in 1D immunoblot are indicated,
adjusted to membrane background.
Found at: doi:10.1371/journal.pone.0010079.s001 (0.07 MB
DOC)
Figure S2 2D-Westernblot of Fibulin-1. Illustration of 2D
immunoblots with Fibulin-1 antibody in BM (left) as well as VM
(right). The Westernblots show different isoform patterns of this
protein in the meningitis samples.
Found at: doi:10.1371/journal.pone.0010079.s002 (0.97 MB
DOC)
Figure S3 MS-spectra
Found at: doi:10.1371/journal.pone.0010079.s003 (0.21 MB
PDF)
Table S1 Additional data of protein identification. Columns 4–6
refer to PMF searches; columns 7–9 refer to MS/MS ion searches.
Found at: doi:10.1371/journal.pone.0010079.s004 (0.05 MB
DOC)
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